Treatment with lurasidone ( vs placebo ) was associated with significantly greater reductions in MADRS scores in the mixed features group ( -@ vs -@ ; P = @ ; week @ ; mixed model for repeated measures -LSB- MMRM -RSB- ; effect size , @ ) and in the group without mixed features ( -@ vs -@ ; P = @ ; week @ ; MMRM ; effect size , @ ) .